pLIVE Vector Complete System – 20 ug of each vector

The Promoter in the pLIVE® Vector Outperforms the CMV Promoter for Long-term Liver Expression. The pLIVE®-SEAP Vector (20 µg) and pCMV-SEAP (10 µg, CMV promoter-driven SEAP vector) were each delivered to four ICR mice using the hydrodynamic tail vein injection procedure and the TransIT®-QR Hydrodynamic Delivery Solution (MIR 5240). At the indicated days post-injection, serum from each mouse was collected and the level of SEAP activity present was determined using the Phospha-Light™ SEAP Assay Kit (Applied Biosystems). The average SEAP activity from each group is presented.

Long-term Expression of Human Placental Secreted Alkaline Phosphatase (SEAP) in Mice after Hydrodynamic Delivery of the pLIVE®-SEAP Vector. The pLIVE®-SEAP Vector was delivered to three C57Bl/6 mice using the hydrodynamic tail vein injection procedure and the TransIT®-QR Hydrodynamic Delivery Solution (MIR 5240). At the indicated times post-injection, serum from each mouse was collected and the level of SEAP activity was determined using the Phospha-Light™ SEAP Assay Kit (Applied Biosystems). Average SEAP activity at each time point is presented.

Strong Liver Expression of ß-galactosidase from pLIVE®-lacZ Vector after Hydrodynamic Tail Vein Injection. The pLIVE®-lacZ Vector (Panel A) was delivered to an ICR mouse using the hydrodynamic tail vein injection procedure and the TransIT®-QR Hydrodynamic Delivery Solution (MIR 5240). At 24 hours post-injection, the liver was harvested, sectioned and stained with X-gal to demonstrate ß-galactosidase activity (blue cells). The cells were then counterstained with hematoxylin and eosin Y to stain the nuclei and cytoplasms, respectively. The control mouse (lacZ negative) in Panel B was stained in parallel to Panel A and contains no detectable ß-galactosidase activity.